Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is market cap of Melinta Therapeutics Inc?
The market cap of Melinta Therapeutics Inc is $1.51M
What is the 52 week high for Melinta Therapeutics Inc?
The 52 week high for Melinta Therapeutics Inc is $8.60.
What is the 52 week low for Melinta Therapeutics Inc?
The 52 week low for Melinta Therapeutics Inc is $0.06.
What is the pe ratio of Melinta Therapeutics Inc?
The PE ratio of Melinta Therapeutics Inc is 0.00.
What is the price to book ratio of Melinta Therapeutics Inc?
The price to book ratio of Melinta Therapeutics Inc is -0.0250.
What is the 50-day moving average of Melinta Therapeutics Inc?
The 50-day moving average of Melinta Therapeutics Inc is 0.1458.